LPLaura Pattyn

Laura Pattyn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Pattyn has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of a Personalized, High-Dose, Intensive Motor Rehabilitation Program, Integrating Advanced Technology for Adults With Central Neurological Conditions (INTeRAcT): Protocol for a Single-Blind Randomized Controlled Trial With a Clinical, Health Economic, and Process Evaluation

    by Marjan Coremans, Ingue Allewijn, Filiep Bataillie, Laure De Bruyn, Maaike Fobelets, Femke Jacobs, Sienke Janssens, Laura Pattyn, Koen Putman, Agaat Schiltz, et al.

    Background: Chronic stroke and spinal cord injury (SCI) lead to persistent motor impairments that reduce independence and quality of life. Although rehabilitation is essential to address these challenges, the amount of therapy provided during the chronic phase remains limited, while the long-term costs of care are substantial. Objective: The INTeRAcT (Intensive Rehabilitation Programme Integrating Advanced Technology) trial investigates a high-dose, intensive-targeted, and personalized rehabilitation program through an integrated clinical, health economic, and process evaluation. Methods: This single-blind randomized controlled trial will include 100 adults in the chronic phase after stroke or SCI. Participants will be randomized to either the INTeRAcT intervention group (n=50) or a control group receiving usual care (n=50). The intervention group will receive 90 hours of personalized motor rehabilitation over 3 weeks, including upper and lower limb therapy, with and without technology, cardiovascular fitness training, and self-management education. Both groups then resume usual care and are followed for 9 months. Clinical assessments are performed at baseline (T0), after 3 weeks (T1, postintervention), and after 9-months follow-up (T2) by a blinded assessor. The primary outcome is independence in daily life, assessed using the Functional Independence Measure for stroke and the Spinal Cord Independence Measure for SCI. Secondary outcomes include the EQ-5D-5L, Canadian Occupational Performance Measure, Goal Attainment Scaling, Fatigue Severity Scale, and stroke-specific measures such as the Action Research Arm Test, Fugl-Meyer Assessment, 6-Minute and 10-Meter Walk-Test, and the Stroke Self-Efficacy Questionnaire. Group differences in clinical change will be analyzed using multivariate linear models. Health economic data will be collected using diaries and questionnaires, capturing direct and indirect costs. Cost-effectiveness will be assessed through a trial-based cost-utility analysis over 9 months and a Markov model over a lifetime horizon. The process evaluation follows the UK Medical Research Council framework, using mixed methods with quantitative and qualitative data from diaries, interviews, and observations, analyzed descriptively and thematically. Results: The funding of the project started in February 2023. Protocol version 5 (accepted March 15, 2024). Participant recruitment occurred between June 2023 and September 2024, with a total of 102 participants enrolled. Data collection ended in July 2025. Data analysis is ongoing. Conclusions: This protocol outlines a randomized controlled trial integrating clinical, health economic, and process evaluations to assess a high-dose, individualized rehabilitation program. The findings will provide evidence on effectiveness, cost-effectiveness, and implementation feasibility in chronic stroke and SCI, supporting the optimization of long-term neurorehabilitation care.


  • The Speed Precision ObsTacle CourSe (SPOTS): a reliable, valid and sensitive obstacle course for assessing walking adaptability for people with central neurological disorders

    by Vanessa Janssens, Marjan Coremans, Liesel Cornelis, Laure De Bruyn, Charlotte Heremans, Sarah Meyer, Laura Pattyn, Geert Verheyden

    This prospective study examined the psychometric properties of the Speed Precision ObsTacle courSe (SPOTS), a six-item, triangle-shaped obstacle course to assess walking adaptability in individuals with a central neurological disorder (CND). Inter- and intra-rater reliability, validity and sensitivity of the SPOTS were evaluated in adults with CND undergoing inpatient rehabilitation. The SPOTS was performed on 2 consecutive days, and 1 month later, alongside clinical assessments on the first and last day. Completion time was recorded, and three raters performed clinician-rated assessments for motor and cognitive function based on video recordings. Reliability of the clinician-rated SPOTS score was assessed with Intraclass Correlation Coefficients (ICC), Bland-Altman, and weighted Kappa analysis; validity with Spearman rank correlation coefficients and sensitivity to change with the minimal detectable change (MDC). Thirty-five independent walkers (FAC ≥3) with CND were recruited. The SPOTS showed excellent inter-rater (ICC: 0.90-0.93) and intra-rater reliability (ICC: 0.91-0.96). Adequate to excellent correlations (r = 0.36-0.66) were found with other common balance and gait assessments. An MDC value of 4.63 points (6.4% of SPOTS) was found. The SPOTS is a new, promising, reliable, valid and sensitive tool for assessing advanced walking adaptability in patients with CND.

  • Open Access

    Impact of a high-dose intensive-targeted motor rehabilitation programme integrating advanced technology for adults with central neurological conditions (INTeRAcT): protocol for a single-blind randomised controlled trial with a clinical, health economic and process evaluation

    by Marjan Coremans, Ingue Allewijn, Filiep Bataillie, Laure De Bruyn, Maaike Fobelets, Femke Jacobs, Sienke Janssens, Laura Pattyn, Koen Putman, Agaat Schiltz, et al.

    Introduction: Chronic stroke and spinal cord injury are both associated with persistent motor impairments, resulting in reduced independence in daily life and lower quality of life. Although rehabilitation is essential to address these challenges, the amount of therapy provided during the chronic phase remains limited, while the long-term cost of care is substantial. Here, we describe the INTeRAcT protocol: a randomised controlled trial with a clinical, health economic and process evaluation, designed to assess the effectiveness of a high-dose, intensive-targeted and personalised rehabilitation programme. Methods and analysis: In this single-blind randomised controlled trial, we aim to recruit 100 adults in the chronic phase after stroke or spinal cord injury. Participants will be randomised to either the INTeRAcT intervention group (n=50) or a control group receiving usual care (n=50). The intervention group will receive 90 hours of personalised motor rehabilitation over three weeks, including upper and lower limb therapy, with and without advanced technology, cardiovascular fitness training, and self-management education. After the intervention, both groups return to usual care and are followed up for nine months. Clinical outcomes will be assessed by a blinded assessor at baseline (T0), post-intervention (T1), and at nine-month follow-up (T2), with additional data collected throughout for the health economic and process evaluations. The primary clinical outcome is independence in daily life, assessed using the Functional Independence Measure for participants with stroke, and the Spinal Cord Independence Measure for those with spinal cord injury. Secondary clinical outcomes include the EuroQol 5D-5L, Canadian Occupational Performance Measure, Goal Attainment Scaling, and the Fatigue Severity Scale. Additional stroke-specific secondary outcomes are the Action Research Arm Test, Fugl-Meyer Assessment, Functional Ambulation Categories, the 6 Minute Walk Test, 10 Meter Walk Test, and the Stroke Self-Efficacy Questionnaire. A multivariate linear model will be used to compare clinical changes between the two groups. Health economic data will be collected using diaries and questionnaires, capturing direct and indirect costs such as healthcare use, medication, transport, productivity loss, and informal care. Effects will be measured via the EQ-5D-5L and expressed in Quality-Adjusted Life Years. Cost-effectiveness will be assessed through a trial-based cost-utility analysis over a nine-month horizon and a Markov model over a lifetime horizon, complemented by scenario analyses and a budget-impact analysis. The process evaluation, guided by the UK Medical Research Council framework, adopts a mixed-methods approach combining quantitative and qualitative data from structured diaries, semi-structured interviews, and observations. Quantitative data will be presented descriptively, while qualitative data will be examined using both content and thematic analysis. Ethics and dissemination: Ethical approval was obtained from the central and local ethics committees on 10 July 2023. The currently approved protocol is version 5, dated 15 March 2024. All participants provide written informed consent prior to enrolment. Study findings will be disseminated through peer-reviewed journals and presentations at national and international conferences, as well as at various stakeholder events. Trial registration number: NCT05970367 (31 July 2023) ARTICLE SUMMARY: Strengths and limitations of this study: This protocol combines clinical, process, and health economic evaluations to comprehensively assess a complex, high-dose and individually tailored motor rehabilitation intervention, addressing key evidence gaps regarding effectiveness, implementation, contextual factors and cost-effectiveness in chronic stroke and spinal cord injury care. Clinical outcome assessments will be conducted by a blinded assessor, reducing the risk of measurement bias. The rehabilitation programme combines a standardised structure with individual goal-setting, developed in collaboration with clinical practice and grounded in evidence-based principles, enhancing feasibility and clinical applicability. Although the trial is conducted in a single clinical centre, the inclusion of both stroke and spinal cord injury populations enhances generalisability across neurological conditions, while the process evaluation will identify contextual factors to support future implementation in other settings.